• Tien-Li Lan, Cheng-Ying Shiau, Ling-Wei Wang, Yu-Ming Liu, Yi-Wei Chen, Pin-I Huang, Yu-Wen Hu, I-Chun Lai, Yuan-Hung Wu, Tzu-Yu Lai, Yu-Mei Kang, Wan-Chin Yang, Yu-Jung Lin, Yi-Ying Pan, Chi-Chuan Chiu, Ching-Sheng Liu, Tung-Sheng Hsieh, Jia-Cheng Lee, Fang-Yi Lin, Chien-Hsuan Chan, Hui-Chia Lin, and Keng-Li Lan.
• Department of Heavy Particles and Radiation Oncology, Taipei Veterans General Hospital, Taipei, Taiwan, ROC.
• J Chin Med Assoc. 2025 Jan 16.

BackgroundUnlike conventional photon radiotherapy, particle therapy has the advantage of dose distribution. Carbon-ion radiotherapy is also advantageous in terms of biological effectiveness and other radiobiological aspects. These benefits lead to a higher response probability for previously known radioresistant tumor types. Therefore, Taipei Veterans General Hospital, which is located in the northern district of Taipei, built the first carbon-ion irradiation facility in Taiwan.MethodsTaipei Veterans General Hospital completed a phase 1 trial to evaluate the safety of carbon-ion radiotherapy. Six patients (4 males and 2 females with prostate adenocarcinoma, sacral chordoma, hepatocellular carcinoma, lung adenocarcinoma, or parotid high-grade carcinoma) were enrolled in this study. The mean age of the patients was 62.7 years. The mean dose was 57.3 Gy(RBE) (fraction range, 4-16 Gy(RBE)).ResultsDuring this phase 1 trial, all patients were monitored for 3 months to evaluate acute toxicity and short-term outcomes after treatment with carbon irradiation. Only 2 patients experienced grade 2 toxicity, which resolved without medication 1 month after completing treatment. The tumor response demonstrated 1 complete response, 1 partial response, and 4 cases of stable disease.ConclusionCarbon-ion radiotherapy was determined to be an effective and safe treatment.Copyright © 2025, the Chinese Medical Association.

8 keywords...

hide…